Siddhartha Mukherjee, oncologist and author of “The Emperor of All Maladies,” asks: What if we change what a tumor can eat?

Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...

Researchers in Japan have shown that the mitochondrial protein COX7RP extends healthy lifespan in mice by enhancing ...

Reportedly distributed across nearly 75% of the country, the product in question "fails to declare" one very important ingredient.

Glioblastoma is the most common form of brain cancer in adults, and its consequences are usually quick and fatal. After ...

Confused about protein recommendations? We asked protein experts on what exactly is the answer. Plus, everything else you ...

Patients whose cancers ​were hormone receptor (HR) negative – that is, their tumor cells did not have proteins that bind to ...

A research team at Florida State University's Institute of Molecular Biophysics and Department of Chemistry and Biochemistry ...

Two scientists at the Johns Hopkins School of Medicine have been selected for membership in the National Academy of Inventors ...

This research led to Balu-Iyer founding the Buffalo-based company Immune Modulatory Therapies LLC in 2019. His UB co-founders ...

Trastuzumab deruxtecan (T-DXd; Enhertu), is a HER2-targeting ADC that is used in ET-treated HER2-low or HER2-ultralow disease and offered meaningful results in DESTINY-Breast04. In a 2025 real-world ...

The first-line standard of care for HR-positive/HER2-negative breast cancer is cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET). This dual-therapy targets a pathway ...